# A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

> **NCT04079296** · PHASE1,PHASE2 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 43 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** ASP7517

## Key facts

- **NCT ID:** NCT04079296
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-19
- **Primary completion:** 2023-04-21
- **Final completion:** 2023-04-21
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04079296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04079296, "A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04079296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*